Tedec-Meiji Farma
CompanySpain
Tedec-Meiji Farma develops 4 assets, the furthest in phase 3 (Chondroitin sulfate in knee osteoarthritis). Mostly supplement and small molecule; based in Spain.
- 4
- Assets
- Furthest stage
- Phase 3
- 2
- Trials
- 6
- Signals
Pipeline
4Sulfated glycosaminoglycan providing cartilage matrix structural support and reducing inflammatory signaling in joints.
Phase 3, Supplement, knee osteoarthritis, dry eye syndrome
Chondroitin sulfate+glucosamine sulfate
Supports cartilage matrix maintenance and may reduce joint inflammation.
Phase 3, no development reported, Small molecule, knee osteoarthritis, osteoarthritis
Supports cartilage matrix synthesis and maintenance.
Phase 3, no development reported, Small molecule, back pain, knee osteoarthritis
1 more asset
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials2
- Signals20
- Similar companies6